Details of Disease

General Information of Disease (ID: DISEXWC3)

Disease Name Chronic lymphocytic leukaemia
Disease Class 2A82: Mature B-cell leukaemia
Disease Hierarchy
DIS01GPL: Grass pollen hypersensitivity
DISEXWC3: Chronic lymphocytic leukaemia
ICD Code
ICD-11
ICD-11: 2A82.0
ICD-10
ICD-10: C83.0, C91.1
Expand ICD-11
'2A82.0
Disease Identifiers
MONDO ID
MONDO_0003864
UMLS CUI
C1302547
MedGen ID
224906

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 14 Approved Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Acalabrutinib DM7GCVW Approved NA [1]
Alemtuzumab DMZL3IV Approved Antibody [2]
Chlorambucil DMRKE63 Approved Small molecular drug [3]
GDC-0199 DMH0QKA Approved Small molecular drug [4]
Idelalisib DM602WT Approved Small molecular drug [5]
Obinutuzumab DM3BVAE Approved Antibody [6]
Ofatumumab DM295PR Approved Antibody [7]
Pirtobrutinib DMRG1X3 Approved Small molecular drug [8]
Tafasitamab DMPIDFL Approved Antibody [9]
Tisagenlecleucel DMM9BJD Approved CAR T Cell Therapy [1]
Ublituximab DMHTY9W Approved Antibody [1]
Umbralisib DMYRBO1 Approved NA [1]
Venetoclax DM8I94Y Approved Small molecular drug [10]
Zanubrutinib DMJWRQP Approved NA [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 14 Drug(s)
This Disease is Treated as An Indication in 88 Clinical Trial Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
ABT-199 DM2BLMT Phase 3 NA [11]
BI-695500 DMT0NTL Phase 3 NA [1]
GP2013 DMZB45J Phase 3 NA [12]
ICP-022 DMU72KL Phase 3 Small molecular drug [13]
RG7601 DMDVAFP Phase 3 NA [14]
MOR-208 DMDQOWT Phase 2/3 Antibody [15]
ALXN6000 DMH5LFR Phase 2 Antibody [16]
APX005M DMX2P5G Phase 2 Antibody [17]
AZD6738 DM0PFNC Phase 2 Small molecular drug [18]
BI-836826 DMWH7Z5 Phase 2 Antibody [1]
CART-19 DMHQKN6 Phase 2 CAR T Cell Therapy [19]
CC-292 DMJR9H0 Phase 2 Small molecular drug [20]
Cirmtuzumab DM98RW0 Phase 2 NA [21]
Cobomarsen DMF4MX9 Phase 2 NA [1]
CTL019 DMMPC6W Phase 2 CAR T Cell Therapy [22]
DTRM-555 DMX27IT Phase 2 Small molecular drug [23]
Flavopiridol DMKSUOI Phase 2 Small molecular drug [24]
IL-2/CD40L-expressing leukemia vaccine DMIHQ5G Phase 2 Vaccine [25]
INVAC-1 DMYM72J Phase 2 Vaccine [26]
ISF35 DMBZK3P Phase 2 NA [27]
LAM-002 DMR0N74 Phase 2 NA [28]
Lirilumab DMNGT89 Phase 2 Monoclonal antibody [12]
LMB-2 DMG7RAV Phase 2 NA [29]
ME-401 DMK0UOY Phase 2 Small molecular drug [1]
MEDI-551 DMBTVFE Phase 2 Antibody [30]
Odronextamab DMP6NVV Phase 2 Antibody [31]
Otlertuzumab DMAZIND Phase 2 NA [1]
REGN1979 DMSJ3Z5 Phase 2 NA [1]
RP6530 DMYILGK Phase 2 NA [32]
Veltuzumab DM5BL4C Phase 2 Monoclonal antibody [33]
ACP-319 DM7IWTF Phase 1/2 NA [34]
Anti-CD19 CAR transduced T cells DMHSLVJ Phase 1/2 CAR T Cell Therapy [35]
Anti-CD19 CAR-T cells DMDRYZK Phase 1/2 CAR T Cell Therapy [36]
Anti-CD19/22-CAR vector-transduced T cells DMMUSHR Phase 1/2 CAR T Cell Therapy [37]
APG-2575 DMPWBM2 Phase 1/2 Small molecular drug [38]
AR-42 DML44FR Phase 1/2 Small molecular drug [39]
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes DM2YTGQ Phase 1/2 CAR T Cell Therapy [40]
BI 1206 DMTOMWB Phase 1/2 Antibody [41]
CD19 CAR T Cells DMUARWH Phase 1/2 CAR T Cell Therapy [42]
CD19.CAR T Cells DM79GPF Phase 1/2 CAR T Cell Therapy [43]
CD20-Specific CAR T Cells DMHPZ8G Phase 1/2 CAR T Cell Therapy [44]
CLL immunotherapeutic vaccine DMYZWJ2 Phase 1/2 NA [45]
Eptacog beta DMTY96S Phase 1/2 Small molecular drug [46]
FBT-A05 DMQSF5C Phase 1/2 Antibody [47]
GLG-801 DMY1CP9 Phase 1/2 NA [1]
IOV-2001 DMRWHJT Phase 1/2 Cell therapy [48]
JCAR017 DMJV2IF Phase 1/2 CAR T Cell Therapy [49]
JCARH125 DM8P7FC Phase 1/2 CAR T Cell Therapy [49]
Milatuzumab DM4H7UY Phase 1/2 Antibody [50]
Monalizumab DMG7XHE Phase 1/2 Antibody [1]
PBCAR20A DM7NKWQ Phase 1/2 CAR T Cell Therapy [51]
PCAR-019 DM9DR13 Phase 1/2 CAR T Cell Therapy [52]
SNX-5422 DMIU0VP Phase 1/2 Small molecular drug [1]
TP-0903 DMHTG8P Phase 1/2 NA [53]
TRU-016 DM9IQ4A Phase 1/2 NA [54]
ZX-101A DM65AV2 Phase 1/2 Small molecule [55]
Anti-CD19 "armored" CAR-Tcell therapy DMQYK7Y Phase 1 NA [12]
BIBX-1382 DM79XGM Phase 1 Small molecular drug [56]
BMS-986403 DMC7B1B Phase 1 NA [57]
CAR-20/19-T Cells DM4CXE2 Phase 1 CAR T Cell Therapy [58]
CC-122 DM0SRAN Phase 1 Small molecular drug [1]
CD19 CAR T Cells DMCUBFR Phase 1 CAR T Cell Therapy [59]
CD19.CAR-aNKT cells DMMO2EJ Phase 1 CAR T Cell Therapy [60]
DTRMWXHS-12 DM5AGKV Phase 1 Small molecular drug [1]
EGFRt/19-28z/4-1BBL CAR T cells DMZN35T Phase 1 CAR T Cell Therapy [61]
FT-819 DMGJNTQ Phase 1 CAR T Cell Therapy [62]
GNKG-168 DMYWDT4 Phase 1 NA [63]
GS-9820 DMNX3US Phase 1 NA [64]
HMPL-760 DMHC5YG Phase 1 NA [65]
JBH492 DM7XAV1 Phase 1 Antibody drug conjugate [66]
JNJ-64264681 DMLYAGD Phase 1 NA [67]
JNJ-67856633 DM6URNJ Phase 1 NA [68]
JNJ-75348780 DMSDSFX Phase 1 Bispecific antibody [69]
MS-553 DM7ER9J Phase 1 NA [70]
NKX019 DMOQDN0 Phase 1 CAR-NK cell therapy [71]
NX-2127 DMIE2OG Phase 1 Small molecule [72]
NX-5948 DM6GHMC Phase 1 Small molecule [73]
Oncoquest-CLL DM1XWIJ Phase 1 NA [74]
OTSSP167 DMF5KNO Phase 1 Small molecular drug [1]
PRT-062607 DMBL7CW Phase 1 Small molecular drug [75]
PSB202 DM5RGU8 Phase 1 NA [76]
ROR1 CAR-specific Autologous T-Lymphocytes DM5EUIY Phase 1 CAR T Cell Therapy [77]
SUN-K0706 DMIF8RY Phase 1 NA [1]
TG-1701 DMNDHKL Phase 1 Small molecular drug [78]
VIP-152 DMBQ5OL Phase 1 Small molecule [79]
YTB323 DM5BMIO Phase 1 CAR T Cell Therapy [80]
Anti-CD19/20-CAR vector-transduced T cells DM3M9OY Clinical trial CAR T Cell Therapy [81]
CAP-100 DM1CVX3 Clinical trial Antibody [82]
------------------------------------------------------------------------------------
⏷ Show the Full List of 88 Drug(s)
This Disease is Treated as An Indication in 3 Discontinued Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
AGS-005 DM2A6IU Discontinued in Phase 1/2 NA [83]
ALD-151 DMYKGIA Discontinued in Phase 1 NA [84]
Enloplatin DM0YFLR Terminated Small molecular drug [88]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 4 Preclinical Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
BI-D1870 DMK3SAF Preclinical Small molecular drug [85]
D-4476 DMHD3R8 Preclinical Small molecular drug [86]
PF-4800567 DM8P9ST Preclinical Small molecular drug [86]
PF-670462 DMTJBP9 Preclinical Small molecular drug [87]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 5 Investigative Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Alpha-type-1 polarized dendritic cells DM7ULCB Investigative NA [89]
CD-160130 DMT6M5E Investigative NA [90]
DXL-625 DMZWAQ3 Investigative NA [91]
Leukozene DM9YOBL Investigative NA [89]
LNA anti-miR-155 DMT9VHT Investigative NA [89]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6770).
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7143).
4 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6741).
6 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6941).
7 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6778).
8 ClinicalTrials.gov (NCT04666038) Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With CLL or SLL. U.S. National Institutes of Health.
9 Clinical pipeline report, company report or official report of Xencor.
10 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
11 Clinical pipeline report, company report or official report of Abbott Laboratories.
12 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
13 ClinicalTrials.gov (NCT04578613) ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL. U.S. National Institutes of Health.
14 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034622)
15 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
16 ClinicalTrials.gov (NCT00648739) Safety and Dose Ranging Study of ALXN6000 to Treat Relapsing or Refractory CLL or MM. U.S. National Institutes of Health.
17 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1874).
18 ClinicalTrials.gov (NCT01955668) AZD6738 First Time in Patient Multiple Ascending Dose Study. U.S. National Institutes of Health.
19 ClinicalTrials.gov (NCT01029366) CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy
20 Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans. J Pharmacol Exp Ther. 2013 Aug;346(2):219-28.
21 ClinicalTrials.gov (NCT04501939) Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax (Venetoclax). U.S. National Institutes of Health.
22 ClinicalTrials.gov (NCT02445248) Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients. U.S. National Institutes of Health.
23 ClinicalTrials.gov (NCT04305444) Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas. U.S. National Institutes of Health.
24 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5680).
25 ClinicalTrials.gov (NCT01604031) Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells + Lenalidomide. U.S. National Institutes of Health.
26 ClinicalTrials.gov (NCT03265717) DNA Plasmid Encoding a Modified Human Telomerase Reverse Transcriptase (hTERT), Invac-1 in Chronic Lymphocytic Leukemia. U.S. National Institutes of Health.
27 ClinicalTrials.gov (NCT00942409) Study of Repeat Intranodal Injection of Memgen's Cancer Vaccine, Ad-ISF35, in Subjects With Non-Hodgkin's Lymphoma (Follicular, Diffuse Large Cell, Mantle Cell, and Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia. U.S. National Institutes of Health.
28 ClinicalTrials.gov (NCT02594384) A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma (LAM-002A/NHL) (LAM-002A/NHL). U.S. National Institutes of Health.
29 Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol. 2000 Apr;18(8):1622-36.
30 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7992).
31 ClinicalTrials.gov (NCT02290951) An Open-Label, Multi-Center Phase 1 Study to Investigate the Safety and Tolerability of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients With CD20+ B-Cell Malignancies Previously Treated With CD20-Directed Antibody Therapy (ELM-1). U.S.National Institutes of Health.
32 ClinicalTrials.gov (NCT04204057) Efficacy and Safety of Tenalisib (RP6530) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). U.S. National Institutes of Health.
33 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8268).
34 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800040955)
35 ClinicalTrials.gov (NCT03191773) A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies
36 ClinicalTrials.gov (NCT02851589) Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma
37 ClinicalTrials.gov (NCT03185494) Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22
38 ClinicalTrials.gov (NCT04494503) Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL. U.S. National Institutes of Health.
39 Clinical pipeline report, company report or official report of Arno Therapeutics.
40 ClinicalTrials.gov (NCT01865617) Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia
41 ClinicalTrials.gov (NCT02933320) BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia. U.S. National Institutes of Health.
42 ClinicalTrials.gov (NCT01475058) CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant
43 ClinicalTrials.gov (NCT03676504) Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR
44 ClinicalTrials.gov (NCT03277729) A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
45 Clinical pipeline report, company report or official report of MaxCyte.
46 ClinicalTrials.gov (NCT04419389) APR-246 in Combination With Ibrutinib or Venetoclax-R in Subjects With TP53-Mutant R/R Non Hodgkin Lymphomas (NHL) (R/R). U.S. National Institutes of Health.
47 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030721)
48 ClinicalTrials.gov (NCT04155710) Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL. U.S. National Institutes of Health.
49 ClinicalTrials.gov (NCT03436771) Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product
50 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8267).
51 ClinicalTrials.gov (NCT04030195) Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL. U.S. National Institutes of Health.
52 ClinicalTrials.gov (NCT02819583) CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma
53 ClinicalTrials.gov (NCT03572634) Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL. U.S. National Institutes of Health.
54 ClinicalTrials.gov (NCT01188681) Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia. U.S. National Institutes of Health.
55 ClinicalTrials.gov (NCT05269940) A Phase I/II Study Evaluating ZX-101A in Patients With Relapsed/Refractory Hematological Malignancies. U.S.National Institutes of Health.
56 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7646).
57 ClinicalTrials.gov (NCT05244070) A Phase 1, Multicenter, Open-label Study of BMS-986403 in Subjects With Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). U.S.National Institutes of Health.
58 ClinicalTrials.gov (NCT03375619) Long-term Follow-up Study of Patients Receiving CAR-20/19-T Cells
59 ClinicalTrials.gov (NCT01853631) Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
60 ClinicalTrials.gov (NCT03774654) CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)
61 ClinicalTrials.gov (NCT03085173) A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies
62 ClinicalTrials.gov (NCT04629729) FT819 in Subjects With B-cell Malignancies. U.S. National Institutes of Health.
63 ClinicalTrials.gov (NCT01743807) Phase I Study of GNKG168 in Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia. U.S. National Institutes of Health.
64 Clinical pipeline report, company report or official report of Gilead.
65 ClinicalTrials.gov (NCT05176691) A Multicenter, Open-label, Phase 1 Study Evaluating the Safety and Tolerability of HMPL-760 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Other Non-Hodgkin Lymphoma (NHL). U.S.National Institutes of Health.
66 ClinicalTrials.gov (NCT04240704) Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL). U.S. National Institutes of Health.
67 ClinicalTrials.gov (NCT04210219) A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia. U.S. National Institutes of Health.
68 ClinicalTrials.gov (NCT03900598) A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL). U.S. National Institutes of Health.
69 ClinicalTrials.gov (NCT04540796) A Phase 1, First-in-Human, Dose Escalation Study of the JNJ-75348780 Bispecific Antibody Targeting CD3 and CD22 in Participants With NHL and CLL. U.S.National Institutes of Health.
70 ClinicalTrials.gov (NCT03492125) A Study Of The Selective PKC-beta Inhibitor MS- 553. U.S. National Institutes of Health.
71 ClinicalTrials.gov (NCT05020678) A Phase 1 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects With B-cell Malignancies. U.S.National Institutes of Health.
72 ClinicalTrials.gov (NCT04830137) A Phase 1, Dose Escalation, Safety and Tolerability Study of NX-2127, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults With Relapsed/Refractory B-cell Malignancies. U.S.National Institutes of Health.
73 ClinicalTrials.gov (NCT05131022) A Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults With Relapsed/Refractory B-cell Malignancies. U.S.National Institutes of Health.
74 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
75 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8070).
76 ClinicalTrials.gov (NCT05003141) A Phase 1a/1b Study of PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies. U.S.National Institutes of Health.
77 ClinicalTrials.gov (NCT02706392) Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies
78 ClinicalTrials.gov (NCT03671590) Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies. U.S. National Institutes of Health.
79 ClinicalTrials.gov (NCT04978779) An Open-label, Multicenter Phase 1/1b Study to Characterize Safety, Tolerability, Preliminary Antitumor Activity, Pharmacokinetics, and Pharmacodynamics of VIP152 Monotherapy or Combination Therapy in Subjects With High-risk Chronic Lymphocytic Leukemia or Richter Syndrome. U.S.National Institutes of Health.
80 ClinicalTrials.gov (NCT03960840) CD19-specific CAR-T Cells in CLL/SLL and DLBCL. U.S. National Institutes of Health.
81 ClinicalTrials.gov (NCT03097770) Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20
82 ClinicalTrials.gov (NCT04704323) An Open Label Phase Ia/b Dose Escalation Followed by Dose Expansion Safety and Tolerability Trial of CAP-100, a Humanized C-C-chemokine Receptor 7 Antibody, Administered as Monotherapy in Subjects With r/r Chronic Lymphocytic Leukemia. U.S.National Institutes of Health.
83 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023550)
84 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029586)
85 BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo. Biochem J. 2007 Jan 1;401(1):29-38.
86 Circadian rhythm as a therapeutic target. Nat Rev Drug Discov. 2021 Apr;20(4):287-307.
87 Casein kinase 1 is a therapeutic target in chronic lymphocytic leukemia. Blood. 2018 Mar 15;131(11):1206-1218.
88 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002455)
89 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
90 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1300).
91 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2628).